Curated News
By: NewsRamp Editorial Staff
May 18, 2026

Lantern Pharma Cuts R&D Costs 47% While Advancing AI Drug Platform

Discuss on Substack
Original Source

TLDR

  • Lantern Pharma cut R&D spending 47% year-over-year, extended runway to Q1 2027, and launched withZeta.ai for new revenue.
  • Lantern Pharma advanced LP-300 Phase 2 trial after FDA Type C meeting and received IND clearance for pediatric CNS cancer program.
  • Lantern's AI platform withZeta.ai accelerates drug development for cancers including pediatric CNS tumors, improving patient outcomes.
  • Lantern Pharma plans to spin off its AI assets into an independent entity, focusing on multi-agentic drug discovery.

Impact - Why it Matters

This news matters because Lantern Pharma's 47% reduction in R&D spending while advancing clinical programs demonstrates how AI can significantly lower drug development costs, potentially making precision oncology more accessible and affordable. The launch of withZeta.ai as a commercial platform also signals a shift toward AI-driven drug discovery becoming a revenue-generating service, which could accelerate innovation across the biomedical industry. For investors, the extended runway into 2027 provides confidence in the company's financial stability, while for patients, the progress on LP-300 and pediatric CNS programs offers hope for new treatments in underserved areas.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced its first-quarter 2026 operational highlights and financial results, showcasing a 47% year-over-year reduction in research and development spending while advancing multiple clinical programs. Key milestones include a successful FDA Type C meeting outcome for the Phase 2 HARMONIC trial of LP-300 and IND clearance for Starlight Therapeutics’ first pediatric CNS cancer program. The company also launched withZeta.ai, its multi-agentic AI drug development platform, which is now commercially available as a subscription-based research platform, creating a new revenue stream. Lantern outlined plans to separate its AI assets into an independent entity and secured financing of up to $9.25 million, extending its operating runway into the first quarter of 2027.

Lantern Pharma is leveraging its proprietary RADR® platform to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma after TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For the full press release, visit https://ibn.fm/R1C54.

Additionally, AINewsWire, a specialized communications platform focusing on AI advancements, covered this news. AINewsWire is part of the Dynamic Brand Portfolio @ IBN, delivering press release distribution, editorial syndication to 5,000+ outlets, and social media distribution. AINewsWire aims to cut through information overload to provide clients with brand awareness and recognition. For more information, visit www.AINewsWire.com or text “AI” to 888-902-4192.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Cuts R&D Costs 47% While Advancing AI Drug Platform

blockchain registration record for this content.